Thus, the ratio between follistatin and activin A should determine activin A’s ability to inhibit BMP-6 or BMP-9, both with regards to myeloma cell apoptosis and to osteoblastogenesis. The gene discussed is GDF2; the disease is plasma cell myeloma.